AI Article Synopsis
- Chromosome 22q11.2 deletion syndrome (22q11.2DS) is a common genetic condition that can lead to various health issues, particularly immune deficiencies due to thymus problems.
- In a study of 87 patients, most were diagnosed around 1.78 months old and frequently had congenital heart disease, major infections, and growth issues, with significant associations found with autoimmune disorders and neuropsychiatric problems.
- Overall, while some immunological issues like T lymphopenia may improve over time, patients need continuous health monitoring, as factors like recurrent infections and heart problems can heavily affect survival rates.
Article Abstract
Background: Chromosome 22q11.2 deletion syndrome (22q11.2DS) is the most common microdeletion syndrome in humans and can present with highly variable clinical manifestations. Immune deficiencies occur because of thymic hypoplasia or aplasia.
Methods: This retrospective study included patients diagnosed with 22q11.2DS at a medical center between 2000 and 2021. We analyzed the association between clinical phenotypes, immunological abnormalities, age, and outcomes.
Results: Eighty-seven patients with 22q11.2DS had a median diagnostic age of 1.78 months. Patients presented with congenital heart disease (CHD; 86.2%), major infections (75.9%), and failure to thrive (FTT; 58.6%). Autoimmunity, neuropsychiatric disorders, and hypoparathyroidism were significantly associated. Neonatal seizures were associated with early diagnosis before 2 months (OR 8.56, 95% CI 1.21-60.58, P = 0.032). Immunological abnormalities included lymphopenia (93.1%), T lymphopenia (71.9%), CD4 T lymphopenia (64.1%), a lack of hepatitis B vaccine antibodies (46.2%), and complete DiGeorge syndrome (cDGS) (2.3%). Severe lymphopenia and T lymphopenia improved at 3 years of age. Two patients with cDGS were treated with hematopoietic stem cell transplantation, and one survived. The mortality rate was 12.8% and the estimated 35-year survival probability was 77.5%. Major infections experienced > four times were significantly associated with a decreased survival rate of 60%. Patients with CHD without FTT or recurrent infections had a better 20-year survival rate (96.2%).
Conclusions: CHD, major infection, and FTT were common manifestations and poor prognostic factors. Autoimmunity, neuropsychiatric disorders, and hypoparathyroidism were significantly associated. Although T lymphopenia may improve with age, patients with 22q11.2DS require lifelong monitoring for immune dysregulation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10875-022-01340-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case Report: Autoimmune Psychosis in Chromosome 22q11.2 Deletion Syndrome.
Front Immunol
December 2021
Neuroimmunology and Neuroinflammation Group, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain.
Chromosome 22q11.2 deletion syndrome (22q11DS) is characterized by congenital cardiac abnormalities, hypoplastic thymus, palatal abnormalities, and hypocalcemia, although other clinical features are frequent such as autoimmune and psychiatric disorders. One-third of the patients have psychotic disorders, frequently followed by developmental regression and long-term cognitive disturbances.
View Article and Find Full Text PDFCase Report: Ménière's Disease-Like Symptoms in 22q11.2 Deletion Syndrome.
Front Neurol
June 2021
Department of Neurology, Pusan National University School of Medicine, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, South Korea.
Article Synopsis
- The 22q11.2 deletion syndrome (22q11.2DS) is a genetic disorder linked to various health issues, including heart defects, developmental delays, and hearing impairments due to ear malformations.
- A case study describes a 38-year-old male with 22q11.2DS who experienced fluctuating hearing loss and vertigo similar to Ménière's disease over a decade.
- Medical tests revealed issues like abnormal ear structures and endolymphatic hydrops, suggesting that problems with fluid flow in the ear can lead to acute vertigo and hearing loss in individuals with 22q11.2DS.
The paper presents a clinical case of congenital cleft palate as a manifestation of 22q11.2 deletion syndrome accompanied by other systemic disorders having direct impact on functional indicators and perioperative period during cleft surgery. Specific for 22q11.
View Article and Find Full Text PDFArticle Synopsis
- - Chronic myeloid leukaemia (CML) cells feature a small chromosome 22 due to a translocation of most of its q arm to chromosome 9.
- - The researcher used cell hybrids with different parts of chromosome 22 to locate the c-sis oncogene, which is known to be on chromosome 22.
- - Findings indicate that the c-sis oncogene is located between the CML breakpoint (22q112) and 22q13, confirming its translocation to chromosome 9 in CML cells.
The authors discuss the clinical and cytogenetic problems raised in two new cases of X-chromosome translocations. The first case involves a child who presented marked malformations at age 3 months. Chromosome analysis revealed the presence of a translocation between a 22 and X chromosome resulting in partial X monosomy and partial trisomy 22: 46,X,der(X),t(X:22)(q112;q13)mat.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!